Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Uridine monophosphate kinase as potential target for tuberculosis: from target to lead identification.

Arvind A, Jain V, Saravanan P, Mohan CG.

Interdiscip Sci. 2013 Dec;5(4):296-311. doi: 10.1007/s12539-013-0180-y. Epub 2014 Jan 10.

PMID:
24402823
3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.

Hosen MI, Tanmoy AM, Mahbuba DA, Salma U, Nazim M, Islam MT, Akhteruzzaman S.

Interdiscip Sci. 2014 Mar;6(1):48-56. doi: 10.1007/s12539-014-0188-y. Epub 2014 Jan 28.

PMID:
24464704
5.

Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening.

Saxena S, Devi PB, Soni V, Yogeeswari P, Sriram D.

J Mol Graph Model. 2014 Feb;47:37-43. doi: 10.1016/j.jmgm.2013.08.005. Epub 2013 Sep 18.

PMID:
24316937
6.

Structural and functional characterization of the Mycobacterium tuberculosis uridine monophosphate kinase: insights into the allosteric regulation.

Labesse G, Benkali K, Salard-Arnaud I, Gilles AM, Munier-Lehmann H.

Nucleic Acids Res. 2011 Apr;39(8):3458-72. doi: 10.1093/nar/gkq1250. Epub 2010 Dec 10.

7.

Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.

Uddin R, Siddiqui QN, Azam SS, Saima B, Wadood A.

Eur J Pharm Sci. 2017 Nov 22;114:13-23. doi: 10.1016/j.ejps.2017.11.014. [Epub ahead of print]

PMID:
29174549
8.

Virtual Screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis.

Garg A, Tewari R, Raghava GP.

BMC Bioinformatics. 2010 Jan 18;11 Suppl 1:S53. doi: 10.1186/1471-2105-11-S1-S53.

9.

A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.

Shen H, Wang F, Zhang Y, Huang Q, Xu S, Hu H, Yue J, Wang H.

FEBS J. 2009 Jan;276(1):144-54. doi: 10.1111/j.1742-4658.2008.06763.x. Epub 2008 Nov 20.

10.

Structure-based in-silico rational design of a selective peptide inhibitor for thymidine monophosphate kinase of mycobacterium tuberculosis.

Kumar M, Sharma S, Srinivasan A, Singh TP, Kaur P.

J Mol Model. 2011 May;17(5):1173-82. doi: 10.1007/s00894-010-0821-6. Epub 2010 Aug 11.

PMID:
20697760
11.

Structural basis of mapping the spontaneous mutations with 5-flurouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis.

Ghode P, Jobichen C, Ramachandran S, Bifani P, Sivaraman J.

Biochem Biophys Res Commun. 2015 Nov 20;467(3):577-82. doi: 10.1016/j.bbrc.2015.09.133. Epub 2015 Oct 8.

PMID:
26456658
13.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
14.

Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.

Khare G, Kar R, Tyagi AK.

PLoS One. 2011;6(7):e22441. doi: 10.1371/journal.pone.0022441. Epub 2011 Jul 26.

15.

Efficient heterologous expression and one-step purification of fully active c-terminal histidine-tagged uridine monophosphate kinase from Mycobacterium tuberculosis.

Penpassakarn P, Chaiyen P, Palittapongarnpim P.

Southeast Asian J Trop Med Public Health. 2011 Nov;42(6):1452-9.

PMID:
22299415
16.

Comprehensive structural and functional characterization of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (Mtb-MurA) and prediction of its accurate binding affinities with inhibitors.

Babajan B, Chaitanya M, Rajsekhar C, Gowsia D, Madhusudhana P, Naveen M, Chitta SK, Anuradha CM.

Interdiscip Sci. 2011 Sep;3(3):204-16. doi: 10.1007/s12539-011-0100-y. Epub 2011 Sep 29.

PMID:
21956743
17.

Purine Salvage Pathway in Mycobacterium tuberculosis.

Ducati RG, Breda A, Basso LA, Santos DS.

Curr Med Chem. 2011;18(9):1258-75. Review.

PMID:
21366536
18.

Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase.

Van Calenbergh S, Pochet S, Munier-Lehmann H.

Curr Top Med Chem. 2012;12(7):694-705. Review.

PMID:
22283813
19.

Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis.

Anishetty S, Pulimi M, Pennathur G.

Comput Biol Chem. 2005 Oct;29(5):368-78. Epub 2005 Oct 6.

PMID:
16213791
20.

Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.

Kumar R, Garg P, Bharatam PV.

J Biomol Struct Dyn. 2015;33(5):1082-93. doi: 10.1080/07391102.2014.929535. Epub 2014 Jun 23.

PMID:
24875451

Supplemental Content

Support Center